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ABSTRACT
Objectives  To compare the efﬁ  cacy of disease activity 
score in 28 joints (DAS28ESR)-driven therapy with anti-
tumour necrosis factor (patients from the GUEPARD trial) 
and routine care in patients with recent-onset rheumatoid 
arthritis (patients of the ESPOIR cohort).
Results  After matching GUEPARD and ESPOIR patients 
on the basis of a propensity score and a 1:2 ratio, at 
baseline all patients had comparable demographic 
characteristics, rheumatoid factor, anticyclic citrullinated 
peptide antibody positivity and clinical disease activity 
parameters: erythrocyte sedimentation rate, C-reactive 
protein, mean DAS (6.26±0.87), Sharp/van der 
Heijde radiographic score (SHS), health assessment 
questionnaire (HAQ). Disease duration was longer 
in GUEPARD patients (5.6±4.6 vs 3.5±2.0 months, 
p<0.001). After 1 year, the percentage of patients 
in remission with an HAQ (<0.5) and an absence of 
radiological progression was higher in the tight control 
group (32.3% vs 10.2%, p=0.011) as well as the 
percentage of patients in low DAS with an HAQ (<0.5) 
and an absence of radiological progression (36.1% vs 
18.9%, p=0.045). However, there was no difference in 
the decrease in DAS, nor in the percentage of EULAR 
(good and moderate), ACR20, ACR50 and ACR70 
responses. More patients in the tight control group had 
an HAQ below 0.5 (70.2% vs 45.2%, p=0.005). Overall, 
pain, patient and physician assessment and fatigue 
decreased more in the tight control group. The mean SHS 
progression was similar in the two groups as was the 
percentage of patients without progression.
Conclusions  In patients with recent onset active 
rheumatoid arthritis, a tight control of disease activity 
allows more patients to achieve remission without 
disability and radiographic progression.
The management of early rheumatoid arthritis 
(RA) has evolved rapidly over the past decade as 
emphasised in the last EULAR recommendations 
for the management of RA.1 Synthetic disease-
modifying antirheumatic drugs (DMARD) should 
be started as soon as the diagnosis of RA is made 
and methotrexate is considered as the anchor 
drug.1 Biological agents, particularly tumour 
necrosis factor (TNF) inhibitor, have proved to 
be more effective than methotrexate as treatment 
for patients with newly diagnosed RA.2 Finally, 
patients with early active disease may beneﬁ  t 
from an active steering and prompt adjustment of 
treatment intensity.3 GUEPARD is a prospective 
unblinded randomised multicentre controlled 
1-year trial comparing two initial treatment strate-
gies (initial methotrexate monotherapy vs its com-
bination with adalimumab) in patients with early 
and active RA (<6 months, DAS28 >5.1).4 In both 
groups, treatment was adjusted every 3 months 
with the aim of achieving a low DAS (DAS28ESR 
<3.2) by the use of TNF blockers. We hypothesised 
that the systemic measurement of disease activity 
with adjustments to therapy according to a ﬁ  xed 
protocol based mainly on anti-TNF results in a bet-
ter clinical improvement and radiographic outcome 
than the routine care administered to patients of 
the ESPOIR cohort.5
MATERIALS AND METHODS
Patients
In the GUEPARD study patients with early RA, 
as deﬁ   ned by the 1987 criteria of the American 
College of Rheumatology (ACR; formerly the 
American Rheumatism Association), were recruited 
between May 2004 and May 2006 in 13 centres in 
France. Patients had a maximum disease duration 
of 6 months, were at least 18 years of age, and had 
active disease deﬁ  ned as a disease activity score in 
28 joints (DAS28ESR) greater than 5.1. They were 
randomly assigned to receive methotrexate mono-
therapy (group 1, n=32; methotrexate 0.3 mg/kg 
per week, maximum of 20 mg/kg per week, with-
out escalating dose regimen) or initial combination 
therapy (group 2, n=33) with methotrexate (same 
regimen as group 1) and adalimumab (40 mg every 
other week). In both groups, treatment was adjusted 
every 3 months. The aim was to achieve a low dis-
ease activity state (DAS28ESR <3.2). For example, 
in the event of persistent active disease at month 3, 
adalimumab was added (group 1) or increased 
to 40 mg/week (group 2). Three months later, in 
the event of a low disease activity state , metho-
trexate was continued for a further 3 months and 
thereafter the dose was slowly tapered (group1) or 
adalimumab was decreased for 3 months and then 
discontinued at month 9 and thereafter restarted in 
the event of ﬂ  are (group 2).4
The ESPOIR cohort is a nationwide, longitudi-
nal, prospective cohort of 813 patients established 
by the French Society for Rheumatology to inves-
tigate the diagnosis, outcome markers, epidemiol-
ogy, pathogenesis and medico-economics of early 
arthritis and RA.5 The cohort was constituted by 
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best goodness of ﬁ  t of matched pairs. The statistical power for 
a 1:1 matching was too low (71%) in comparison with a 1:2 
matching (83%), assuming a comparison of two binomial pro-
portions of 40% (n=65) versus 20% (n=65 or 130). Moreover, 
when the matching procedure was applied to a 1:3 matching, 
the goodness of matched pairs was lower than the 1:2 matching. 
Consequently, the 1:2 matching was computed.
Statistical analysis
All matched patients (n=195) were included in an intent-to-
study analysis of efﬁ  cacy and safety. For radiographic criteria, 
missing evaluations at month 12 (N=10/195) were replaced by 
linear regression imputation using baseline and month 6 evalu-
ations. For all other criteria, missing data (from 2.7% to 4.8%) 
were replaced using linear regression between previous and next 
values, if available. Otherwise, last observation carried forward 
methodology was used. At baseline, comparability between 
groups was assessed using Student’s t tests or Fisher’s exact 
tests. After 6 months and 1 year, both groups were compared 
using analyses of covariance for continuous data or logistic 
regression models for discrete data. The strategy group (tight 
control vs routine practice), the mean daily dosage of corticos-
teroids and the duration of biotherapy during the study were 
used as covariates. p Values less than 0.05 were considered sta-
tistically signiﬁ  cant.
RESULTS
At baseline, all patients in the tight control group (n=65) and 
routine practice group (n=130) fulﬁ  lled the ACR 1987 criteria. 
They had comparable demographic characteristics (female 
77%, age 48.0±13.0 years), RF and anti-CCP positivity (67.2% 
and 63.6%), swollen and tender joint counts (10.5±5.5 and 
14.0±6.8), patient’s assessment of global disease activity 
(68.0±20.8 mm), pain (57.0±21.2 mm), fatigue (54.7±26.3 mg), 
doctor’s assessment (66.5±17.8 mg) of disease activity on a 
0–100 mg VAS, ESR (38.7±24.6 mg ﬁ  rst hour), CRP (29.4±32.6 
mg/l), typical erosive disease (17.9%), modiﬁ   ed total SHS 
(6.5±10.1), erosion score (2.4±4.2), narrowing score (4.1±7.1), 
HAQ (1.3±0.6), physical (35.5±7.9) and mental components 
(37.5±11.5) of SF36. All patients had a DAS score above 5.1 
(mean 6.26±0.87). The tight control group had a longer mean 
disease duration than the routine practice group (5.6±4.6 vs 
3.5±2.0 months, p<0.001; table 1). All patients in the GUEPARD 
trial but only 74.8% in the ESPOIR cohort received methotrex-
ate (p<0.0001). Other patients in ESPOIR cohort received sul-
phasalazine (9.2%), leﬂ  unomide (5.2%) or hydroxychloroquine 
(7.7%). None received combination DMARD therapy. More 
patients in the GUEPARD trial received anti-TNF than in the 
ESPOIR cohort (89% vs 13.08%, p<0.0001). In contrast, more 
patients in the ESPOIR cohort received corticosteroids (67% 
vs 43%, p=0.002) with a greater cumulative dose (3316±1842 
vs 1808±1110, p<0.0001) and mean dose (8.66±8.51 mg vs 
4.86±3.27 mg, p=0.0009). Thirteen patients received intra-
articular steroid injections in the GUEPARD study and 38 in the 
ESPOIR cohort (p=0.2).
After 1 year, the percentage of patients in remission with 
an HAQ (<0.5) and an absence of radiological progression was 
higher in the tight control group (32.3% vs 10.2%, p=0.011) as 
well as the percentage of patients in low DAS with an HAQ 
(<0.5) and an absence of radiological progression (36.1% vs 
18.9%, p=0.045; ﬁ  gure 1). However, there was no difference in 
the decrease in DAS (tight control: −3.12±1.82; routine practice: 
−2.65±1.66, p=0.12), nor in the percentage of patients in low 
having general practitioners and rheumatologists refer patients 
with early arthritis to hospitals participating in the ESPOIR 
cohort project. Patients were eligible for inclusion in the cohort 
if they had a deﬁ  nitive or probable clinical diagnosis of RA or 
a diagnosis of undifferentiated arthritis with potential for pro-
gressing to RA. Patients were included if they met the follow-
ing criteria: age over 18 years and less than 70 years, swelling 
of two or more joints for 6 weeks, symptom duration of less 
than 6 months and no previous treatment with DMARD or glu-
cocorticoids. However, the use of glucocorticoids for no longer 
than 2 weeks with a mean dosage of no greater than 20 mg per 
day and discontinuation at least 2 weeks earlier did not prevent 
study inclusion. Patients who were included in the cohort were 
assessed every 6 months for 2 years and then once a year for at 
least 10 years.
Assessment of variables
In the GUEPARD study and in the ESPOIR cohort the follow-
ing variables were assessed: number of swollen joints (0–28); 
number of tender joints (0–28); visual analogue scale (VAS) 
score for pain (0–100 mm); VAS general wellbeing (0–100); 
VAS fatigue (0–100); VAS physician overall assessment (0–100); 
morning stiffness (min); erythrocyte sedimentation rate (ESR, 
mm/h1st) and C-reactive protein (CRP, mg/l). These variables 
were assessed monthly in the GUEPARD study, and at weeks 
0, 24 and 52 in the ESPOIR cohort. The French version of the 
health assessment questionnaire (HAQ) was ﬁ  lled out at weeks 
0, 12, 24, 36 and 52 in the GUEPARD study and at weeks 0, 
24 and 52 in the ESPOIR cohort. (0–3=greatest functional dis-
ability).  Rheumatoid factor (RF) and anticyclic citrullinated 
peptide antibody (anti-CCP) status was deﬁ  ned at baseline. 
Radiographs of hands and feet were taken at baseline, at week 
24 and at week 52 in the GUEPARD study and at baseline 
and week 52 in the ESPOIR cohort. Radiographs were inde-
pendently scored by a trained assessor (CL), who was blinded 
to the patient’s identity and treatment centre according to the 
modiﬁ  ed Sharp/van der Heijde score (SHS), with a range of 0 
to 448. A patient was classiﬁ  ed as having erosive disease if the 
erosion score was greater than 1.
Matching methodology
Patients included in the ESPOIR cohort who fulﬁ  lled the inclu-
sion criteria of the GUEPARD trial (DAS ≥5.1, ACR 1987 crite-
ria fulﬁ  lled) without any participation in a study protocol and 
no missing baseline data were eligible (n=277) for the matching 
procedure. In order to reduce bias in baseline measured charac-
teristics, patients were then matched using the propensity score, 
ie, the predicted probability of a patient belonging to the tight 
control study. The propensity score was computed using a mul-
tivariate logistic regression model. All demographic and disease 
characteristics at baseline were used as covariates in the model: 
centre, gender, age at inclusion, disease duration, body mass 
index, RF and anti-CCP status, ESR, CRP, tender and swollen 
joint count (28), patient’s assessments of pain, disease activity, 
fatigue and doctor’s assessment of disease activity on a 0–100 mm 
VAS, HAQ, physical and mental components of SF36, erosive 
disease, erosion score and narrowing score. The propensity 
score was reliable because the overall model ﬁ  t probability was 
less than 10−4 and the area under the receiver operating charac-
teristic curve (95% CI) was 0.76 (0.71 to 0.83).
The matching procedure used was an iterative process based 
on the least propensity score difference between case and 
control.6 The rule used to determine the number of controls 
to match each case was the highest statistical power with the 
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DAS (tight control: 63.1%; routine practice: 43.8%, p=0.64) 
and in remission (tight control: 47.7%; routine practice: 29.2%, 
p=0.35; table 2 and ﬁ  gure 1). There was no statistically sig-
niﬁ   cant difference in EULAR (good and moderate), ACR20, 
ACR50, and ACR70 responses (93.8% vs 84.6%, p=0.11; 81.5% 
vs 64%, p=0.37; 68.8% vs 41.3%, p=0.43; 50.8% vs 23.6%, 
p=0.07; ﬁ  gure 1). The improvement in HAQ was similar (tight 
control: −0.94±0.82; routine practice: −0.68±0.73, p=0.07) but 
more patients in the tight control group had an HAQ below 0.5 
(70.2% vs 45.2%, p=0.005). Overall, pain, patient and physician 
assessment and fatigue decreased more in the tight control group 
than in the routine practice group (−44.8±31.9 vs −24.2±29.2, 
p<0.001; −46.6±35.6 vs −32.3±32.5, p=0.015; −49.1±32.7 vs 
36.0±29.9, p=0.02; −37.1±36.2 vs −12.2±33.1, p<0.0001). The 
mean SHS progression was similar in the two groups (tight 
control: 0.95±4.6; routine practice: 1.5±4.1, p=0.46) as was the 
percentage of patients without progression (71.19% vs 69.23%, 
p=0.37; table 2). In the GUEPARD trial, malignancy was diag-
nosed in two patients (ovarian carcinoma, pancreatic cancer) 
both of whom were in the methotrexate and adalimumab 
group. No patients had serious infections. The other serious 
adverse events in the GUEPARD trial attributed to the treat-
ment were hepatitis in two patients, methotrexate pneumonia 
in one patient and weight loss in another patient. Seven adverse 
events were observed in the ESPOIR cohort. Two patients had 
dyspnoea related to methotrexate, two had haematemesis, one 
had soft tissue infection (patient on methotrexate), one had 
thrombopaenia related to methotrexate and one had pericarditis 
related to salazopyrin.
Figure 1  Patients in whom response had been achieved at the 12 month assessment. ACR, Americal College of Rheumatology; DAS, disease 
activity score; HAQ, health assessment questionnaire.
0.0 0.1 1.0 10.0
EULAR good response 
Guepard: n= 41 (63.1%)  vs Espoir: n= 57 (43.8%) 
OR (95% CI)= 1.21  ( 0.54 to 2.75 ) 
EULAR remission 
Guepard: n= 31 (47.7%)  vs Espoir: n= 38 (29.2%) 
OR (95% CI)= 1.48  ( 0.65 to 3.35 )
ACR20 
Guepard: n= 53 (81.5%)  vs Espoir: n= 80 (64.0%) 
OR (95% CI)= 1.53  ( 0.61 to 3.88 )
ACR50 
Guepard: n= 44 (68.8%)  vs Espoir: n= 52 (41.3%) 
OR (95% CI)= 1.40  ( 0.61 to 3.24 )
ACR70 
Guepard: n= 33 (50.8%)  vs Espoir: n= 30 (23.6%) 
OR (95% CI)= 2.15  ( 0.94 to 4.92 )
Remission and HAQ < 0.5 and no radiologic progression 
Guepard: n= 20(32.3%)  vs Espoir: n= 13 (10.2%) 
OR (95% CI)= 3.68  ( 1.35 to 10.00 )
Low DAS and HAQ < 0.5 and no radiologic progression 
Guepard: n= 22(36.1%)  vs Espoir: n= 24 (18.9%) 
OR (95% CI)= 2.53  ( 1.02 to 6.25 )
OR (95% CI)
Routine practice
better
Tight control 
better
Table 1 Baseline  characteristics
 
GUEPARD 
(N=65)
ESPOIR 
(N=130) p Value
Age mean±SD (years) 47.9±15.7 48.1±11.5 0.92
Women, n (%) 52 (80.0) 98 (75.4) 0.59
BMI (kg/m2) 26.0±4.7 26.4±5.5 0.59
Symptom duration, months, mean±SD 5.6±4.6 3.5±2.0 <0.001
IgM rheumatoid factor positive, n (%) 46 (70.8) 85 (65.4) 0.52
Anti-CCP positive, n (%) 46 (70.8) 78 (60.0) 0.16
Pain (VAS 0–100) mean ±SD 59.5±22.0 55.7±20.7 0.23
Patient global assessment (VAS 0–100) 
mean±SD
68.1±18.7 67.9±21.9 0.93
Fatigue (VAS 0–100) mean±SD 57.4±23.6 53.4±27.6 0.31
Physician global assessment (VAS 0–100) 
mean±SD
67.6±17.2 65.9±18.1 0.53
Tender joint count (mean±SD) 14.0±6.7 14.1±6.8 0.93
Swollen joint count (mean±SD) 10.1±4.9 10.7±5.7 0.51
ESR (mean±SD) 37.3±22.4 39.5±25.7 0.56
CRP (mg/l) mean±SD 28.7±33.4 29.8±32.3 0.83
DAS28ESR, mean±SD 6.24±0.81 6.27±0.90 0.84
DAS28CRP, mean±SD 5.82±0.86 5.87±0.95 0.72
HAQ score, 0–3 scale, mean±SD 1.37±0.65 1.28±0.67 0.39
Physical component summaries of SF-36 35.4±8.3 35.6±7.8 0.86
Mental component summaries of SF-36 37.7±11.9 37.5±11.3 0.87
Total SHS, 0–448 scale, mean±SD 7.7±13.4 5.8±8.0 0.30
Erosion score, 0–280 scale, mean±SD 2.4±4.9 2.4±3.7 0.97
JSN score, 0–168 scale, mean±SD 5.3±9.5 3.5±5.4 0.15
Typical erosive disease, n (%) 13 (20.0) 22 (16.9) 0.69
BMI, body mass index; CRP, C-reactive protein; DAS28, disease activity score in 28 
joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; 
JSN, joint-space narrowing; SHS, modiﬁ  ed Sharp/van der Heijde score; SF-36, short 
form 36 health survey; VAS, visual analogue scale.
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observed progression in the DAS-driven group suggests that the 
suppression of joint damage progression was better in this group 
than in routine care patients, albeit not to a level of signiﬁ  cance 
(p=0.126).10 The lack of difference in our study could be explained 
by the fact that the investigators of the ESPOIR cohort were 
aware of early RA.11 Therefore, in the ESPOIR cohort, baseline 
tender joint count (>9), abnormal CRP levels and anti-CCP anti-
bodies were closely related to DMARD treatment11 In addition, 
it is likely that the publication of the preliminary results from the 
TICORA study in 2003, by underlining the interest of tight con-
trol, had inﬂ  uenced the therapeutic care of patients of the ESPOIR 
cohort.12 Nevertheless, a tight control of disease activity with 
TNF blockers allows more patients to achieve remission without 
disability and radiographic progression.
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DISCUSSION
In patients with recent-onset active RA, a tight control of disease 
activity with TNF blockers, as implemented in the GUEPARD 
trial, allowed more patients to achieve remission without disabil-
ity and radiographic progression than the routine care adminis-
tered to the patients in the ESPOIR cohort. In addition, patients 
with tight control had better improvements in HAQ, pain, fatigue 
and global assessment of disease activity, suggesting a Hawthorne 
effect.7 However, the decrease in DAS, the number of patients in 
low DAS or in remission and radiographic progression were simi-
lar in the two groups. These results conﬂ  ict with those previously 
observed with conventional DMARD. In the TICORA study the 
decrease in DAS was greater in the intensive group (−3.5 vs −1.9, 
p<0.0001), as was the number of patients in remission (65% vs 
16%, p<00001).8 Patients in the intensive group had a reduced 
progression of erosion score and total Sharp scores, but no dif-
ference was noted in the progression of joint-space narrowing. 
However, the patients assigned to the intensive group were seen 
every month and any swollen joint was injected unless the joint 
had been injected during the previous 3 months or if the patients 
declined. Furthermore, in the ﬁ  rst 3 months of starting a new 
DMARD if 120 mg of triamcilone acetonide was not injected 
intra-articularly, the same dose was given intramuscularly if the 
disease activity score remained more than 2,4. In the CAMERA 
study, all clinical variables (tender and swollen joint counts, pain, 
general wellbeing) improved signiﬁ  cantly in the ﬁ  rst year in the 
intensive strategy group in comparison with the conventional 
strategy group, with the exception, however, of ESR, morning 
stiffness and functional disability.9 The results of radiographic 
progression were unavailable at 1 year. More recently, the results 
of patients receiving sequential monotherapy or step up to com-
bination therapy in the BeSt trial were compared with the results 
of similar RA patients who had received routine care.10 Again, 
patients with DAS-driven therapy despite higher baseline scores 
had better clinical outcomes after 1 year of follow-up. The mean 
HAQ improvement was 0.70 versus 0.55 (p=0.029), the mean 
DAS28 improvement was 2.7 versus 1.9 (p<0.001) and the median 
ESR improvement was 19 mg/h versus 13 mm/h (p=0.011). The 
percentage of patients in clinical remission (DAS28 <2.6) after 1 
year was 31% versus 18% (p=0.005). In the DAS-driven therapy 
group, median SHS progression was 2.0 (expected progression 
7.0), and in routine care patients it was 1.0 (expected progression 
4.4). The larger difference between the expected progression and 
Table 2  Change in disease activity, radiographic damage, physical function and quality of life between baseline and 12 months
  GUEPARD (N=65) ESPOIR (N=130) p Value
DAS28 −3.12 (−3.56 to −2.67) −2.65 (−2.94 to −2.37) 0.12
Tender joint count (range 0–28) −10.1 (−12.4 to −7.9) −9.1 (−10.6 to −7.6) 0.51
Swollen joint count (range 0–28) −7.7 (−9.5 to −5.9) −8.0 (−9.1 to −6.8) 0.84
Pain score (range 0–100 mm VAS) −44.8 (−52.6 to −37.0) −24.2 (−29.2 to −19.1) <0.001
Patient global assessment (range 0–100 mm VAS) −46.6 (−55.3 to −37.9) −32.3 (−37.9 to −26.7) 0.02
Physician global assessment (range 0–100 mm VAS) −49.1 (−57.1 to −41.1) −36.0 (−41.1 to −30.8) 0.02
ESR, mm/h −19.5 (−26.7 to −12.3) −20.6 (−25.3 to −16.0) 0.82
CRP (mg/l) −24.8 (−35.1 to −14.5) −18.8 (−25.5 to −12.1) 0.39
HAQ score (range 0–3) −0.94 (−1.15 to −0.72) −0.68 (−0.81 to −0.55) 0.07
Fatigue (range 0–100 mm VAS) −37.1 (−46.0 to −28.3) −12.2 (−17.9 to −6.5) <0.0001
Physical component summaries of SF-36 (range 0–100) 9.66 (6.73 to 12.59) 8.75 (6.97 to 10.53) 0.64
Mental component summaries of SF-36 (range 0–100) 9.26 (5.38 to 13.14) 3.92 (1.56 to 6.27) 0.04
Erosion score, 0–280 scale 0.4 (−0.6 to 1.3) 1.3 (0.8 to 1.9) 0.12
JSN score, 0–168 scale 0.6 (0.2 to 1.0) 0.2 (0.0 to 0.4) 0.13
Total SHS, 0–448 scale 0.9 (−0.2 to 2.1) 1.5 (0.8 to 2.3) 0.46
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